ArticleScientific reports2025
TIMP4 serves as a novel potential prognostic biomarker for oral squamous cell carcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Bioinformatic Analysis of Contrasting Expression Patterns and Molecular Interactions of TIMPs in Breast Cancer: Implications for Tumor Progression and Survival.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026Article
- Development and validation of a novel palmitoylation-related prognostic signature in head and neck squamous cell carcinoma.Translational cancer research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The abnormal expression of tissue inhibitor of metalloproteinase 4 (TIMP4) is associated with multiple human cancers. However, the role of TIMP4 in oral squamous cell carcinoma (OSCC) remains elusive. Therefore, this study explored the expression profile and prognosis of TIMP4 in OSCC. Tumor and adjacent non-tumor tissues were collected from OSCC patients, and protein expression of TIMP4 was detected through immunohistochemistry (IHC) and positive cell counting. Additionally, The Cancer Genome Atlas-Head and Neck Squamous Cell Carcinoma (TCGA-HNSCC) dataset was used to analyze TIMP4 expression further to determine its relationship with HNSCC clinical characteristics. Kaplan-Meier analysis was used to evaluate survival and prognosis. Meanwhile, the Tumor Immune Estimation Resource (TIMER) database was employed to assess the correlation between TIMP4 expression and tumor immune infiltration. Computational tools were also applied to investigate the involvement of TIMP4 in cancer pathways. Results showed that TIMP4 was decreased in OSCC and HNSCC compared with normal tissues. The decrease in TIMP4 was associated with cancer metastasis, immune suppression and HPV positive, clinical staging. Overall, these findings demonstrate that TIMP4 is significantly reduced in OSCC and HNSCC, and associated with a poor prognosis. Additional investigations are warranted to fully understand the therapeutic potential of TIMP4 in OSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.